SIBO vs Sucrose Malabsorption: Overlapping Symptoms

Functional gastrointestinal disorders like irritable bowel syndrome and small intestinal bacterial overgrowth confound patients and clinicians. Their symptoms—bloating, pain, diarrhea, constipation—overlap extensively, making a clear diagnosis difficult. A 2026 study from Beth Israel Deaconess Medical Center adds another layer to this complexity: 22% of patients who tested negative for SIBO had sucrose malabsorption, and symptoms could not tell these conditions apart. This finding, along with growing research on the microbiome’s role, demands a precise framework for understanding the SIBO-IBS overlap and its diagnostic challenges.

22% of SIBO-Negative Patients Had Sucrose Malabsorption

Ramprasad, Rangan, and colleagues at Beth Israel Deaconess Medical Center recruited 300 patients referred for SIBO breath testing. After the standard lactulose or glucose breath test for SIBO, participants performed a separate 13C-sucrose breath test at home. Of the 140 patients who completed both tests, 25 of the 113 who were SIBO-negative tested positive for sucrose malabsorption. This translated to a prevalence of 22% in this subgroup.

Symptoms Failed as a Diagnostic Tool

The research team gathered detailed symptom data using the Rome IV criteria, the IBS Severity Scoring System, and the PAGI-SYM index. Analysis revealed no statistically significant differences in predominant symptoms, specific Rome IV diagnoses like IBS or functional constipation, bloating frequency, or symptom severity scores between those with and without sucrose malabsorption. Critically, the symptom profile also could not distinguish sucrose malabsorption from SIBO. The only difference noted was that patients with only sucrose malabsorption reported less abdominal pain than those with only an abnormal SIBO test.

A Third Contributor to Functional Gut Symptoms

“Symptom profile alone did not predict sucrose malabsorption, nor distinguish between sucrose malabsorption and SIBO,” the authors concluded. This work confirms that carbohydrate malabsorption syndromes are a significant, under-recognized contributor to the symptom pool often attributed to IBS or SIBO. It moves the clinical conversation beyond a binary SIBO-or-IBS framework, introducing a third, physiologically distinct entity that produces an almost identical clinical picture. This directly impacts diagnosis, as assuming symptoms indicate SIBO could lead to unnecessary antibiotic courses while missing a dietary cause.

Defining the Overlapping Conditions

The clinical overlap exists because IBS, SIBO, and carbohydrate malabsorption all disrupt normal digestive function in the small intestine, albeit through different mechanisms.

Irritable Bowel Syndrome: A Disorder of Gut-Brain Interaction

IBS is classified as a disorder of gut-brain interaction. Diagnosis is based on the Rome IV criteria: recurrent abdominal pain related to defecation or associated with a change in stool frequency or form, lasting at least three months. It is subtyped as IBS with diarrhea (IBS-D), constipation (IBS-C), mixed (IBS-M), or unclassified. There is no single diagnostic test; diagnosis requires ruling out other organic diseases. As noted in a Japanese review, emotional stress is a principal risk factor, believed to exacerbate symptoms through the gut-brain axis.

Small Intestinal Bacterial Overgrowth: An Anatomical or Motility Problem

SIBO is defined by an excessive number or abnormal type of bacteria in the small intestine. It is not a primary diagnosis but rather a complication of underlying issues that impair small intestinal motility (like diabetic gastroparesis) or anatomy (like surgical blind loops). Bacteria ferment carbohydrates prematurely, producing hydrogen, methane, and other gases that cause bloating, distension, and altered motility. Diagnosis typically relies on hydrogen and methane breath testing after ingesting a sugar substrate like lactulose or glucose.

Why Symptoms Converge: Gas, Osmosis, and Motility

The symptom overlap stems from shared final pathways. In SIBO, bacterial fermentation creates gas. In carbohydrate malabsorption (like sucrose or lactose intolerance), undigested sugars draw water into the intestine via osmosis and are then fermented by colonic bacteria, also producing gas. Both processes lead to bloating, pain, and diarrhea. Altered gut motility, central to IBS, can itself predispose to SIBO by allowing bacteria to stagnate, creating a vicious cycle. This biological convergence is why a patient’s description of “bloating and diarrhea” is diagnostically unhelpful on its own.

The Diagnostic Dilemma and Imperative for Testing

The Beth Israel study makes a clear case: symptom-based diagnosis is insufficient and leads to misdirected treatment. Differentiating these conditions requires objective testing, but even this path has complexities.

Breath Testing: A Tool with Limitations

Breath testing for hydrogen and methane is the most common non-invasive method for SIBO. However, its accuracy can be affected by preparation, the substrate used, and interpretation criteria. A positive test suggests bacterial overgrowth is contributing to symptoms, but it does not rule out co-existing IBS or carbohydrate malabsorption. As the study employed, specialized breath tests like the 13C-sucrose breath test are needed to identify specific enzyme deficiencies.

Research on our site has shown breath testing’s utility in specific populations, such as identifying SIBO in 50% of patients with chronic intestinal pseudo-obstruction (SIBO Found in 50% of CIPO Patients via Breath Test), highlighting its role when motility is severely impaired.

The Exclusion Process: Ruling Out Mimickers

A thorough diagnostic workup for overlapping IBS-like symptoms must systematically exclude other conditions. This typically includes:

• Celiac disease: via serology and possibly endoscopy.
• Inflammatory bowel disease: via calprotectin stool test and colonoscopy.
• Bile acid malabsorption: via SeHCAT test or therapeutic trial.
• Carbohydrate malabsorption: via breath tests for lactose, fructose, and sucrose, or elimination diets.
• SIBO: via hydrogen/methane breath test.

Only after these are investigated should a diagnosis of a pure disorder of gut-brain interaction like IBS be solidified. This process acknowledges that “IBS” is often a diagnosis of exclusion that may encompass several treatable sub-conditions.

Treatment Pathways Diverge Based on Cause

Accurate differentiation is not academic; it determines effective treatment. Treating all symptoms as one condition can lead to treatment failure and patient frustration.

When the Cause is SIBO: Targeting Bacteria

If breath testing confirms SIBO, treatment focuses on reducing bacterial overgrowth. The non-absorbed antibiotic rifaximin is a first-line therapy, particularly for hydrogen-dominant SIBO, and has strong evidence for improving symptoms in IBS-D patients (Rifaximin Eases IBS-D & SIBO with Fewer Side Effects). Prokinetic medications to improve small intestinal motility are often used subsequently to prevent recurrence. Dietary strategies like a low-FODMAP diet can reduce fermentable substrates and ease symptoms but are usually considered adjunctive to antimicrobial treatment.

When the Cause is Carbohydrate Malabsorption: Dietary Modification

For conditions like sucrose or lactose malabsorption, treatment is strictly dietary. This involves identifying and avoiding the specific poorly absorbed sugar. Enzyme replacement supplements (e.g., lactase for lactose) can sometimes be used. The low-FODMAP diet, which systematically restricts several fermentable carbohydrates, is a highly effective strategy for managing functional bloating and pain, with studies showing it reduces symptoms in over 90% of IBS patients (Low FODMAP Diet Reduces IBS Symptoms in 90.7%).

When the Cause is IBS-D or IBS-C: Gut-Brain and Motility Approaches

For IBS where SIBO and malabsorption are ruled out, treatment targets visceral hypersensitivity, motility, and the gut-brain axis. Options include:

• Neuromodulators: Low-dose antidepressants like tricyclics for IBS-D or SSRIs for IBS-C can reduce pain and modulate gut nerves.
• Gut-Directed Therapies: Rifaximin is also FDA-approved for IBS-D, likely due to its subtle microbiome-modifying effects. Antispasmodics like hyoscine can relieve cramping.
• Behavioral Therapies: Cognitive behavioral therapy and gut-directed hypnotherapy have robust evidence for improving symptoms by addressing brain-gut communication.
• Emerging Strategies:

  💊 Popular supplements

  Available on iHerb (ships to 180+ countries):

  Magnesium Glycinate ↗
  NAC ↗
  Vitamin D3 ↗
  Omega-3 ↗

  Affiliate disclosure: we may earn a small commission at no extra cost to you.